LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Combined Tests Improve Tuberculous Meningitis Diagnosis

By LabMedica International staff writers
Posted on 21 Feb 2016
Print article
The T-SPOT.TB enzyme-linked immunospot test kit for tuberculosis
The T-SPOT.TB enzyme-linked immunospot test kit for tuberculosis (Photo courtesy of OXFORD IMMUNOTEC - A Revvity Company)
At present, there is no established laboratory test to diagnose early tuberculous meningitis and cerebrospinal fluid (CSF) culture sensitivity is low in developing countries and it usually takes several weeks to obtain results with this method.

Tuberculous meningitis (TBM), the most severe form of tuberculosis (TB), accounts for 5% to 10% of extrapulmonary TB and 0.5% of systemic TB worldwide. Those who have contracted this disease have a mortality rate of 20% to 41% in developed countries and 44% to 69% in developing countries.

Scientists at Huashan Hospital Fudan University (Shanghai, China) studied a total of 30 patients who were suspected of having TBM, of whom six were clinically diagnosed as having TBM and 24 as probably harboring the disease. These patients included 24 men and six women, aged between 18 and 79 years, with a mean age of 45 years. The diagnostic criteria for TBM were positive acid-fast (AFS) results or positive CSF culture results for Mycobacterium tuberculosis.

After the first admission of each study participant from the TBM and control patient to the hospital, a 1-mL CSF specimen from each via lumbar puncture was collected. The team also collected cerebrospinal fluid from 10 patients in the TBM group on initial visit and at four weeks, to observe changes. A total of 30 individuals with TBM and 39 control individuals without TBM participated in this study. IFN-γ-secreting T cells were detected by ELISPOT, an enzyme-linked immunospot (T-SPOT.TB, Oxford Immunotec International, Abingdon, UK), and cerebrospinal fluid interferon-γ (cIFN-γ) was detected by enzyme-linked immunosorbent assay (ELISA).

The sensitivity and specificity of peripheral-blood T-SPOT.TB testing in the diagnosis of TBM were 70% and 87%, respectively. The area under the receiver operating characteristic (ROC) curve of cIFN-γ (greater than 81.36 pg/mL) for TBM diagnosis was 0.819, and the corresponding sensitivity and specificity were 83% and 85%, respectively. When T-SPOT.TB and cIFN-γ results were positive, the specificity and positive predictive value of TBM diagnosis reached 100%. The consistency is poor between peripheral-blood T-SPOT.TB and cIFN-methods probably due to the factors that could result in false-negative and false-positive results. However, this finding may partially confirm that the combination of these approaches can improve the efficiency of diagnosis of TBM.

The authors concluded that cIFN-γ testing is a rapid, economical, and highly sensitive approach to the diagnosis of TBM. Dynamic observation of cIFN-γ is important for monitoring patients with TBM, a condition that responds well to treatment. Peripheral blood T-SPOT.TB testing for TBM diagnosis is also important. The combination of peripheral blood T-SPOT.TB and cIFN-γ detection can improve overall sensitivity and specificity in the diagnosis of TBM. The study was published on January 4, 2016 in the journal Laboratory Medicine.

Related Links:

Huashan Hospital Fudan University 
Oxford Immunotec International 


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.